WRWael Rayya

Wael Rayya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wael Rayya has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospective Evaluation of Individualized Nutrition Support on the Incidence of High-Output Ileostomy

    by Rahel M. Strobel, Stella Toepfer, Konrad Neumann, Kati Engel, Michael Schumann, Wael Rayya, Christian H. W. Schineis, Katharina Beyer, Arved Weimann, Johannes C. Lauscher

    Background: Patients with an ileostomy are at risk of developing a high-output ileostomy (HOS). An episode of HOS can lead to dehydration and acute kidney injury (AKI). Existing dietary recommendations are largely based on expert opinion. At Charité—Campus Benjamin Franklin, a new interdisciplinary nutrition concept was developed for patients following ileostomy creation. Methods: This prospective, single-centre interventional study included adult patients undergoing elective surgery with the creation of an ileostomy between July 2022 and November 2024. The primary outcome was the incidence of post-discharge HOS occurring during the follow-up period. Patients received standardized postoperative meals and individualized dietary counselling. Outcomes were compared to a historical cohort. Results: Among 103 patients (44.2% female; median age 47.5 years), HOS occurred in 13 patients (12.6%; 95% CI 6.8–20.4%) during follow-up and in 41 of 296 patients in the historical cohort (13.9%; 95% CI, 10.4–18.3%). Patients (n = 23) developing HOS during hospitalization experienced no recurrence at follow-up. Readmission was more frequent in the HOS group (53.8% vs. 21.1%, p = 0.011), particularly due to AKI (46.2% vs. 5.6%, p < 0.001). Weight loss was also more common during follow-up in the group with HOS (76.9% vs. 35.6%, p = 0.005), with a median weight loss of 2 kg. Conclusions: HOS incidence was not different from that observed in the historical cohort; however, the study was not designed to establish equivalence or non-inferiority. The structured nutrition pathway was feasible to implement. Post-discharge HOS was associated with readmission, acute kidney injury, and weight loss.

  • Open Access

    The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma

    by Florian N. Loch, Carsten Kamphues, Katharina Beyer, Christian Schineis, Wael Rayya, Johannes C. Lauscher, David Horst, Mihnea P. Dragomir, Simon Schallenberg

    Immune checkpoint therapy (ICT) has shown promising potential in the treatment of multiple solid tumors. However, the role of ICT in pancreatic ductal adenocarcinoma (PDAC) remains limited. Patterns of immune checkpoints (ICs) in PDAC represent the basis for establishing a potent ICT. The aim of this study is to create a profile of IC expression and its prognostic relevance in cancer cells of PDAC. Therefore, tumor cells from peripheral and central tissue microarray (TMA) spots from histologically confirmed PDAC of 68 patients after tumor resection were investigated in terms of expressions of TIM3, IDO, B7H4, LAG3, VISTA, and PD-L1 using immunohistochemistry. The presence of the respective ICs was compared to overall survival (OS). The presence of VISTA and PD-L1 significantly correlates with shorter OS (median OS: 22 months vs. 7 months and 22 months vs. 11 months, respectively, p < 0.05). For the presence of TIM3, IDO, B7H4, and LAG3, no difference in OS was observed (p > 0.05). The analysis of OS of combined subgroups for VISTA and PD-L1 (VISTA and PD-L1 neg., VISTA pos. and PD-L1 neg., VISTA neg. and PD-L1 pos., and VISTA and PD-L1 pos.) yielded overall statistical significance difference (p = 0.02). These results suggest that the presence of VISTA and PD-L1 is of prognostic relevance and potentially qualifies them as targets for ICT.


  • Open Access

    Peptide Signatures for Prognostic Markers of Pancreatic Cancer by MALDI Mass Spectrometry Imaging

    by Florian N. Loch, Oliver Klein, Katharina Beyer, Frederick Klauschen, Christian Schineis, Johannes C. Lauscher, Georgios A. Margonis, Claudius E. Degro, Wael Rayya, Carsten Kamphues

    Despite the overall poor prognosis of pancreatic cancer there is heterogeneity in clinical courses of tumors not assessed by conventional risk stratification. This yields the need of additional markers for proper assessment of prognosis and multimodal clinical management. We provide a proof of concept study evaluating the feasibility of Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) to identify specific peptide signatures linked to prognostic parameters of pancreatic cancer. On 18 patients with exocrine pancreatic cancer after tumor resection, MALDI imaging analysis was performed additional to histopathological assessment. Principal component analysis (PCA) was used to explore discrimination of peptide signatures of prognostic histopathological features and receiver operator characteristic (ROC) to identify which specific m/z values are the most discriminative between the prognostic subgroups of patients. Out of 557 aligned m/z values discriminate peptide signatures for the prognostic histopathological features lymphatic vessel invasion (pL, 16 m/z values, eight proteins), nodal metastasis (pN, two m/z values, one protein) and angioinvasion (pV, 4 m/z values, two proteins) were identified. These results yield proof of concept that MALDI-MSI of pancreatic cancer tissue is feasible to identify peptide signatures of prognostic relevance and can augment risk assessment.